Oral Atopic Dermatitis Market Crowded, But Arena Sees Room
Executive Summary
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.
You may also be interested in...
Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.